Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sheean ME"'
Autor:
Sheean ME; European Medicines Agency, Amsterdam, Netherlands., Naumann-Winter F; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Capovilla G; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Carlo Poma Hospital, Mantova, Italy.; Fondazione Poliambulanza, Brescia, Italy., Kalland ME; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Statens Legemiddelverk, Oslo, Norway., Malikova E; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; State Institute for Drug Control, Bratislava, Slovakia.; Department of Pharmacology and Toxicology, Comenius University, Bratislava, Slovakia., Mariz S; European Medicines Agency, Amsterdam, Netherlands., Matusevicius D; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Läkemedelsverket, Uppsala, Sweden., Nistico R; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Malta Medicines Authority, San Gwann, Malta., Schwarzer-Daum B; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Medical University of Vienna, Vienna, Austria., Tsigkos S; European Medicines Agency, Amsterdam, Netherlands., Tzogani K; European Medicines Agency, Amsterdam, Netherlands., Larsson K; European Medicines Agency, Amsterdam, Netherlands., Magrelli A; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy., Stoyanova-Beninska V; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; College ter Beoordeling van Geneesmiddelen, Utrecht, Netherlands.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2021 Aug 27; Vol. 8, pp. 744625. Date of Electronic Publication: 2021 Aug 27 (Print Publication: 2021).
Autor:
Tsigkos S; Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands., Mariz S; Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands., Sheean ME; Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands., Larsson K; Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands., Magrelli A; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands., Stoyanova-Beninska V; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, Netherlands.; Medicines Evaluation Board, Utrecht, Netherlands.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2021 Jun 25; Vol. 8, pp. 698534. Date of Electronic Publication: 2021 Jun 25 (Print Publication: 2021).
Autor:
Sheean ME; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands; Max-Delbrück Center for Molecular Medicine in Helmholz Association, Berlin, Germany. Electronic address: maria.sheean@ema.europa.eu., Malikova E; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; State Institute for Drug Control, Bratislava, Slovak Republic; Comenius University, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic., Duarte D; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; INFARMED - Autoridade Nacional do Medicamento, Lisbon, Portugal., Capovilla G; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; C. Poma Hospital, Mantova, Italy; Fondazione Poliambulanza, Brescia, Italy., Fregonese L; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands., Hofer MP; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands., Magrelli A; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy., Mariz S; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands., Mendez-Hermida F; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain., Nistico R; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; Malta Medicines Authority, San Ġwann, Malta., Leest T; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; The Federal Agency for Medicines and Health Products, Brussels, Belgium., Sipsas NV; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; Medical School, National and Kapodistrian University of Athens, Athens, Greece., Tsigkos S; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands., Vitezic D; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia., Larsson K; Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands., Sepodes B; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; INFARMED - Autoridade Nacional do Medicamento, Lisbon, Portugal; Universidade de Lisboa - Faculdade de Farmácia, Lisbon, Portugal., Stoyanova-Beninska V; Committee of Orphan Medicinal Products, European Medicines Agency, Amsterdam, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands.
Publikováno v:
Drug discovery today [Drug Discov Today] 2020 Feb; Vol. 25 (2), pp. 274-291. Date of Electronic Publication: 2019 Nov 05.
Autor:
O'Connor DJ; MHRA, London, UK. daniel.oconnor@mhra.gov.uk., Sheean ME; EMA, London, UK.; MDC, Berlin, Germany., Hofer MP; EMA, London, UK., Tsigkos S; EMA, London, UK., Mariz S; EMA, London, UK., Fregonese L; EMA, London, UK., Larsson K; EMA, London, UK., Hivert V; EURORDIS-Rare Diseases, Europe, France., Westermark K; Former MPA, Uppsala, Sweden., Naumann-Winter F; BfArM, Bonn, Germany., Stoyanova-Beninska V; MEB, Utrecht, Netherlands., Barišić I; Children's University Hospital Zagreb, Zagreb, Croatia., Capovilla G; C. Poma Hospital, Mantova, Italy., Magrelli A; Istituto Superiore di Sanità, Rome, Italy., Sepodes B; University of Lisbon, Lisbon, Portugal.
Publikováno v:
Nature reviews. Drug discovery [Nat Rev Drug Discov] 2019 Jul; Vol. 18 (7), pp. 479-480.
Autor:
Müller T; Developmental Biology/Signal Transduction Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Braud S; Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Jüttner R; Developmental Neurobiology Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Voigt BC; Neural Circuits and Behaviour Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Paulick K; Developmental Biology/Signal Transduction Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Sheean ME; Developmental Biology/Signal Transduction Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Klisch C; Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Gueneykaya D; Cellular Neuroscience Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Rathjen FG; Developmental Neurobiology Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany., Geiger JR; Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Poulet JF; Neural Circuits and Behaviour Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany.; Neuroscience Research Center and Cluster of Excellence NeuroCure, Charité-Universitätsmedizin Berlin, Berlin, Germany., Birchmeier C; Developmental Biology/Signal Transduction Group, Max-Delbrueck-Centrum in the Helmholtz Association, Berlin, Germany cbirch@mdc-berlin.de.
Publikováno v:
The EMBO journal [EMBO J] 2018 Sep 03; Vol. 37 (17). Date of Electronic Publication: 2018 Jul 26.
Autor:
Tsigkos S; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK. Electronic address: stylianos.tsigkos@ema.europa.eu., Hofer MP; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK., Sheean ME; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, Berlin 13125, Germany., Mariz S; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK., Larsson K; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK., Naumann-Winter F; Committee of Orphan Medicinal Products, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK; Bundesinstitut für Arzneimittel und Medizinprodukte Kurt-Georg-Kiesinger-Allee 3, Bonn 53175, Germany., Fregonese L; Orphan Medicines Office, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK., Sepodes B; Committee of Orphan Medicinal Products, European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK; University of Lisbon, Faculty of Pharmacy, Avenida Prof. Gama Pinto, Lisboa 1649-003, Portugal.
Publikováno v:
Drug discovery today [Drug Discov Today] 2018 Mar; Vol. 23 (3), pp. 681-686. Date of Electronic Publication: 2017 Jun 21.
Autor:
Sheean ME; Max-Delbrueck Center for Translational Medicine in the Helmholtz Association, Berlin, Germany; European Medicines Agency, London, UK. Electronic address: maria.sheean@ema.europa.eu., Stoyanova-Beninska V; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands., Capovilla G; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; Child Neuropsychiatry Department, Epilepsy Center, Mantova, Italy., Duarte D; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; INFARMED - Autoridade Nacional do Medicamento, Lisbon, Portugal., Hofer MP; European Medicines Agency, London, UK., Hoffmann M; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; Centre Hospitalier du Nord Ettelbruck, Ettelbruck, Luxembourg., Magrelli A; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy., Mariz S; European Medicines Agency, London, UK., Tsigkos S; European Medicines Agency, London, UK., Shaili E; European Medicines Agency, London, UK., Polsinelli B; European Medicines Agency, London, UK., Ricciardi M; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; Cystic Fibrosis Europe, Brussels, Belgium., Bonelli M; European Medicines Agency, London, UK., Balabanov P; European Medicines Agency, London, UK., Larsson K; European Medicines Agency, London, UK., Sepodes B; Committee of Orphan Medicinal Products, European Medicines Agency, London, UK; Universidade de Lisboa, Faculdade de Farmácia, Lisbon, Portugal.
Publikováno v:
Drug discovery today [Drug Discov Today] 2018 Jan; Vol. 23 (1), pp. 26-48. Date of Electronic Publication: 2017 Oct 04.
Autor:
Sheean ME; Developmental Biology/Signal Transduction., McShane E, Cheret C, Walcher J, Müller T, Wulf-Goldenberg A, Hoelper S, Garratt AN, Krüger M, Rajewsky K, Meijer D, Birchmeier W, Lewin GR, Selbach M, Birchmeier C
Publikováno v:
Genes & development [Genes Dev] 2014 Feb 01; Vol. 28 (3), pp. 290-303.